steroidal

Aromatase inhibitors (AIs) are approved for use in both early and advanced-stage breast cancer in postmenopausal women. Although the currently approved “third-generation” AIs all powerfully inhibit estrogen synthesis, they may be subdivided into steroidal and nonsteroidal inhibitors, which interact with the aromatase enzyme differently. Nonsteroidal AIs bind non- covalently and reversibly to the aromatase protein, [...]